Syncona Regulatory News (SYNC)

Syncona Limited - Directorate Change

PR Newswire

London, October 16

Syncona Limited

Legal Entity Identifier – 213800X8MBI5VQITLW60

Syncona appoints Robert Hutchinson as Non-Executive Director

16 October 2017

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today announces that Robert Hutchinson has been appointed as Non-Executive Director of the Company, with effect from 1 November 2017.

Mr Hutchinson brings many years of broad financial experience to the role, having spent 28 years at KPMG. He was appointed partner in 1999 and specialised in the audit of banking and fund clients. He led the firm’s fund and private equity practices for seven years and served as Head of Audit for KPMG in the Channel Islands for five years until 2013. 

Mr Hutchinson retired from practice in 2014 and is a Fellow of the Institute of Chartered Accountants in England and Wales. He served as President of the Guernsey Society of Chartered and Certified Accountants between 2007 and 2009.

There is no information to be disclosed pursuant to LR 9.6.13R in respect of Mr Hutchinson. As at the date of this announcement, he has no beneficial interests in the ordinary shares of the Company.

[ENDS]

Enquiries

Syncona LtdSiobhan WeaverTel: +44 (0) 20 7611 2031Tulchan CommunicationsMartin RobinsonLisa Jarrett-KerrTel: +44 (0) 207 353 4200

Notes to Editors

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Our current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We are established leaders in gene therapy, cell therapy and advanced diagnostics, and focus on delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by investing in long only and alternative investment funds. This represents a productively deployed evergreen funding base which enables us to take a long term approach to investing in life sciences as we target the best new opportunities and support our existing portfolio companies to grow and succeed.

Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in our business. We make a donation of 0.3% of Net Asset Value to a range of charities each year.